IONS (STOCKS)
Ionis Pharmaceuticals, Inc. Common Stock
$75.174400
+0.004400 (+0.01%)
Prev close: $75.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Brett P. Monia
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $12,381.14M
- Employees
- 927
- P/E (TTM)
- -30.39
- P/B (TTM)
- 25.10
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
13
Buy
7
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.41 | $-1.35 | -0.0624 | -4.63% |
|
Sep 2025 (Q3)
|
$-0.80 | $-1.26 | +0.4582 | +36.42% |
|
Jun 2025 (Q2)
|
$0.70 | $-0.44 | +1.1387 | +259.56% |
|
Mar 2025 (Q1)
|
$-0.93 | $-1.14 | +0.2091 | +18.36% |
Financial Statements
| Revenues | $943.71M |
| Benefits Costs and Expenses | $1.32B |
| Cost Of Revenue | $15.91M |
| Costs And Expenses | $1.33B |
| Gross Profit | $927.80M |
| Operating Expenses | $1.31B |
| Selling, General, and Administrative Expenses | $393.87M |
| Research and Development | $915.62M |
| Operating Income/Loss | -$381.68M |
| Income/Loss From Continuing Operations After Tax | -$381.39M |
| Income/Loss From Continuing Operations Before Tax | -$379.60M |
| Income Tax Expense/Benefit | $1.79M |
| Income Tax Expense/Benefit, Current | $1.79M |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Interest Expense, Operating | $17.26M |
| Net Income/Loss | -$381.39M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$381.39M |
| Net Income/Loss Available To Common Stockholders, Basic | -$381.39M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.38 |
| Diluted Earnings Per Share | -$2.38 |
| Basic Average Shares | 160,010,000 |
| Diluted Average Shares | 160,010,000 |
| Assets | $3.52B |
| Current Assets | $2.99B |
| Inventory | $10.05M |
| Other Current Assets | $2.98B |
| Noncurrent Assets | $533.20M |
| Fixed Assets | $123.05M |
| Other Non-current Assets | $410.15M |
| Liabilities | $3.03B |
| Current Liabilities | $781.57M |
| Accounts Payable | $28.08M |
| Wages | $116.24M |
| Other Current Liabilities | $637.25M |
| Noncurrent Liabilities | $2.25B |
| Long-term Debt | $1.81B |
| Other Non-current Liabilities | $440.78M |
| Equity | $489.09M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $489.09M |
| Liabilities And Equity | $3.52B |
| Net Cash Flow From Operating Activities | -$268.58M |
| Net Cash Flow From Operating Activities, Continuing | -$268.58M |
| Net Cash Flow From Investing Activities | -$277.78M |
| Net Cash Flow From Investing Activities, Continuing | -$277.78M |
| Net Cash Flow From Financing Activities | $675.84M |
| Net Cash Flow From Financing Activities, Continuing | $675.84M |
| Net Cash Flow | $129.48M |
| Net Cash Flow, Continuing | $129.48M |
| Comprehensive Income/Loss | -$375.86M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$375.86M |
| Other Comprehensive Income/Loss | -$375.86M |